Vanda: Vanda Pharma Submits NDA For Bysanti To FDA To Treat Acute Bipolar I Disorder And Schizophrenia

Vanda Pharmaceuticals Inc. (VNDA) announced Monday that a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) requesting marketing approval of Bysanti (milsaperidone) for the treatments of acute bipolar I disorder and schizophrenia. The NDA is supported by several clinical studies assessing the efficacy and safety of Bysanti.